Viral Inactivation Market

The global viral inactivation market was valued at USD 320.5 Million in 2016 and poised to grow at a CAGR of 12.3% between 2016 and 2021, to reach USD 573.0 Million in 2021. Viral inactivation testing is necessary by regulatory authorities for investigational new drug (IND) submission and is mainly critical in process development for biologicals including tissue and tissue products, stem cell products, cellular and gene therapy products, blood and blood products, and vaccine and therapeutics. The major drivers for the market are rapid growth in pharmaceutical and biotechnology industries and strong trend of R&D investments in life sciences industry. Increasing number of new drug launches, rise in chronic disease burden, and increasing government support for the pharmaceutical and biotechnology industries will also aid the growth of this market.

Who Upvoted this Story